Why Teva Pharmaceuticals (TEVA) Stock Is Up Today

NEW YORK (TheStreet) -- Teva Pharmaceuticals  (TEVA) rose Monday after the company unveiled its new organizational structure that trims the size of the executive committee and creates two commercial business units.

The company plans to combine its generic operations into group called Global Generic Medicines. Sigurdur Olafsson, who previously served as president of Actavis PLC, will serve as president and chief executive of the unit. The other group will be Global Specialty Medicines, formed in April 2013. The organizational restructuring also cuts the size of Teva's executive committee from 15 members to 9.

The changes become effective July 1 and the company intends them to provide "seamless global integration, focus and effectiveness across the company," according to Teva's press release.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 2.61% to $51.81 at 12:08 p.m.

TEVA Price Chart

TEVA Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

CEOs Are Dropping Like Flies

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed